Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
AN2 Therapeutics, Inc. | Chief Development Officer | Common Stock | 28.2K | $540K | $19.11 | Mar 15, 2024 | Direct |
AN2 Therapeutics, Inc. | Chief Development Officer | Stock Option (right to buy) | 55K | Mar 15, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
ANTX | AN2 Therapeutics, Inc. | Mar 15, 2024 | 1 | $0 | 4/A | Mar 29, 2024 | Chief Development Officer |
ANTX | AN2 Therapeutics, Inc. | Mar 15, 2024 | 2 | $0 | 4 | Mar 18, 2024 | Chief Development Officer |
ANTX | AN2 Therapeutics, Inc. | Feb 15, 2023 | 1 | $0 | 4 | Feb 17, 2023 | Chief Development Officer |
ANTX | AN2 Therapeutics, Inc. | May 12, 2022 | 1 | $0 | 4 | May 16, 2022 | Chief Development Officer |
ANTX | AN2 Therapeutics, Inc. | Mar 24, 2022 | 0 | $0 | 3 | Mar 24, 2022 | Chief Development Officer |